These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9099519)

  • 1. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance.
    Puga A; Nebert DW; McKinnon RA; Menon AG
    Crit Rev Toxicol; 1997 Mar; 27(2):199-222. PubMed ID: 9099519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms in drug-metabolizing enzymes and drug targets.
    Hiratsuka M; Mizugaki M
    Mol Genet Metab; 2001 Aug; 73(4):298-305. PubMed ID: 11509011
    [No Abstract]   [Full Text] [Related]  

  • 3. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants.
    Nebert DW
    Clin Chem Lab Med; 2000 Sep; 38(9):857-61. PubMed ID: 11097340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation enzyme polymorphism and pesticide susceptibility.
    Eaton DL
    Neurotoxicology; 2000; 21(1-2):101-11. PubMed ID: 10794390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
    Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
    Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of estrogen-related genes jointly confer susceptibility to human spermatogenic defect.
    Su MT; Chen CH; Kuo PH; Hsu CC; Lee IW; Pan HA; Chen YT; Kuo PL
    Fertil Steril; 2010 Jan; 93(1):141-9. PubMed ID: 18980759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.
    Johnson AD; Wang D; Sadee W
    Pharmacol Ther; 2005 Apr; 106(1):19-38. PubMed ID: 15781120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic polymorphisms and cancer susceptibility.
    Smith G; Stanley LA; Sim E; Strange RC; Wolf CR
    Cancer Surv; 1995; 25():27-65. PubMed ID: 8718512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary polymorphisms of human drug metabolizing enzymes and cancer susceptibility.
    Gonzalez FJ
    Birth Defects Orig Artic Ser; 1990; 26(1):17-42. PubMed ID: 2224077
    [No Abstract]   [Full Text] [Related]  

  • 11. [Study of the molecular mechanism of human cytochrome P450 and genetic polymorphism of drug oxidative metabolizing enzyme].
    Zhao L; Lou YQ
    Sheng Li Ke Xue Jin Zhan; 1997 Jan; 28(1):35-40. PubMed ID: 10921075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chapter 21. Additional polymorphisms and cancer.
    Stubbins MJ; Wolf CR
    IARC Sci Publ; 1999; (148):271-302. PubMed ID: 10493263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
    Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.
    Bartsch H; Nair U; Risch A; Rojas M; Wikman H; Alexandrov K
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):3-28. PubMed ID: 10667460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new series of review articles on drug metabolizing enzymes: nomenclature of isoenzyme families, genetic organization, polymorphisms, substrate specificities, clinical relevance and role in carcinogenesis.
    Bolt HM; Hengstler JG
    Arch Toxicol; 2008 Jul; 82(7):413-4. PubMed ID: 18528684
    [No Abstract]   [Full Text] [Related]  

  • 19. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.
    Chacko P; Joseph T; Mathew BS; Rajan B; Pillai MR
    Mutat Res; 2005 Mar; 581(1-2):153-63. PubMed ID: 15725614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.